Clinical Trial: Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284875) titled 'Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes' on Dec. 09.

Brief Summary: The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Obesity Overweight

Intervention: DRUG: KAI-9531

SC Injection

DRUG: Placebo

SC Injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Kailera

Disclaimer: Curated by HT Syndication....